Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2016 - 2025)

Amphastar Pharmaceuticals has reported Capital Expenditures over the past 13 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $1.2 million for Q4 2025, down 90.23% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (down 81.14% YoY), and the annual figure for FY2025 was $7.7 million, down 81.14%.
  • Capital Expenditures for Q4 2025 was $1.2 million at Amphastar Pharmaceuticals, up from $474000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for AMPH hit a ceiling of $33.7 million in Q4 2023 and a floor of -$11.1 million in Q4 2021.
  • Median Capital Expenditures over the past 5 years was $6.1 million (2021), compared with a mean of $6.0 million.
  • Biggest five-year swings in Capital Expenditures: crashed 220.1% in 2022 and later soared 1592.39% in 2024.
  • Amphastar Pharmaceuticals' Capital Expenditures stood at -$11.1 million in 2021, then surged by 285.78% to $20.6 million in 2022, then skyrocketed by 63.42% to $33.7 million in 2023, then tumbled by 63.14% to $12.4 million in 2024, then plummeted by 90.23% to $1.2 million in 2025.
  • The last three reported values for Capital Expenditures were $1.2 million (Q4 2025), $474000.0 (Q3 2025), and -$4.6 million (Q2 2025) per Business Quant data.